Trial Profile
An Open Label, Multicenter Study to Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06 in Pediatric Subjects With Moderate to Severe Plaque Psoriasis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Clobetasol (Primary)
- Indications Plaque psoriasis
- Focus Pharmacokinetics
- Sponsors Encore Dermatology; Promius Pharma
- 10 Sep 2020 Status changed from recruiting to discontinued. Reason the study was stopped: Difficulty in enrolment.
- 12 Feb 2019 Planned End Date changed from 31 May 2018 to 30 Jun 2019.
- 12 Feb 2019 Planned primary completion date changed from 31 May 2018 to 30 Jun 2019.